AcrAB-TolC Inhibition by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers Restores Antibiotic Activity in Vitro and in Vivo

Carolyn R. Sturge, Christina F. Felder-Scott, Reed Pifer, Christine Pybus, Raksha Jain, Bruce L. Geller, David E Greenberg

Research output: Contribution to journalArticle

Abstract

Overexpression of bacterial efflux pumps is a driver of increasing antibiotic resistance in Gram-negative pathogens. The AcrAB-TolC efflux pump has been implicated in resistance to a number of important antibiotic classes including fluoroquinolones, macrolides, and β-lactams. Antisense technology, such as peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs), can be utilized to inhibit expression of efflux pumps and restore susceptibility to antibiotics. Targeting of the AcrAB-TolC components with PPMOs revealed a sequence for acrA, which was the most effective at reducing antibiotic efflux. This acrA-PPMO enhances the antimicrobial effects of the levofloxacin and azithromycin in a panel of clinical Enterobacteriaceae strains. Additionally, acrA-PPMO enhanced azithromycin in vivo in a K. pneumoniae septicemia model. PPMOs targeting the homologous resistance-nodulation-division (RND)-efflux system in P. aeruginosa, MexAB-OprM, also enhanced potency to several classes of antibiotics in a panel of strains and in a cell culture infection model. These data suggest that PPMOs can be used as an adjuvant in antibiotic therapy to increase the efficacy or extend the spectrum of useful antibiotics against a variety of Gram-negative infections.

Original languageEnglish (US)
JournalACS Infectious Diseases
DOIs
StatePublished - Jan 1 2019

Fingerprint

Morpholinos
Anti-Bacterial Agents
Peptides
Azithromycin
Lactams
Levofloxacin
Fluoroquinolones
Macrolides
Enterobacteriaceae
Microbial Drug Resistance
Infection
In Vitro Techniques
Sepsis
Pneumonia
Cell Culture Techniques
Technology

Keywords

  • antisense
  • bacterial efflux pumps
  • Escherichia coli
  • Klebsiella pneumoniae
  • peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs)
  • Pseudomonas aeruginosa

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

AcrAB-TolC Inhibition by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers Restores Antibiotic Activity in Vitro and in Vivo. / Sturge, Carolyn R.; Felder-Scott, Christina F.; Pifer, Reed; Pybus, Christine; Jain, Raksha; Geller, Bruce L.; Greenberg, David E.

In: ACS Infectious Diseases, 01.01.2019.

Research output: Contribution to journalArticle

@article{868d951a57d44e3fbf9d3a9e0eb45f20,
title = "AcrAB-TolC Inhibition by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers Restores Antibiotic Activity in Vitro and in Vivo",
abstract = "Overexpression of bacterial efflux pumps is a driver of increasing antibiotic resistance in Gram-negative pathogens. The AcrAB-TolC efflux pump has been implicated in resistance to a number of important antibiotic classes including fluoroquinolones, macrolides, and β-lactams. Antisense technology, such as peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs), can be utilized to inhibit expression of efflux pumps and restore susceptibility to antibiotics. Targeting of the AcrAB-TolC components with PPMOs revealed a sequence for acrA, which was the most effective at reducing antibiotic efflux. This acrA-PPMO enhances the antimicrobial effects of the levofloxacin and azithromycin in a panel of clinical Enterobacteriaceae strains. Additionally, acrA-PPMO enhanced azithromycin in vivo in a K. pneumoniae septicemia model. PPMOs targeting the homologous resistance-nodulation-division (RND)-efflux system in P. aeruginosa, MexAB-OprM, also enhanced potency to several classes of antibiotics in a panel of strains and in a cell culture infection model. These data suggest that PPMOs can be used as an adjuvant in antibiotic therapy to increase the efficacy or extend the spectrum of useful antibiotics against a variety of Gram-negative infections.",
keywords = "antisense, bacterial efflux pumps, Escherichia coli, Klebsiella pneumoniae, peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs), Pseudomonas aeruginosa",
author = "Sturge, {Carolyn R.} and Felder-Scott, {Christina F.} and Reed Pifer and Christine Pybus and Raksha Jain and Geller, {Bruce L.} and Greenberg, {David E}",
year = "2019",
month = "1",
day = "1",
doi = "10.1021/acsinfecdis.9b00123",
language = "English (US)",
journal = "ACS Infectious Diseases",
issn = "2373-8227",
publisher = "American Chemical Society",

}

TY - JOUR

T1 - AcrAB-TolC Inhibition by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers Restores Antibiotic Activity in Vitro and in Vivo

AU - Sturge, Carolyn R.

AU - Felder-Scott, Christina F.

AU - Pifer, Reed

AU - Pybus, Christine

AU - Jain, Raksha

AU - Geller, Bruce L.

AU - Greenberg, David E

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Overexpression of bacterial efflux pumps is a driver of increasing antibiotic resistance in Gram-negative pathogens. The AcrAB-TolC efflux pump has been implicated in resistance to a number of important antibiotic classes including fluoroquinolones, macrolides, and β-lactams. Antisense technology, such as peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs), can be utilized to inhibit expression of efflux pumps and restore susceptibility to antibiotics. Targeting of the AcrAB-TolC components with PPMOs revealed a sequence for acrA, which was the most effective at reducing antibiotic efflux. This acrA-PPMO enhances the antimicrobial effects of the levofloxacin and azithromycin in a panel of clinical Enterobacteriaceae strains. Additionally, acrA-PPMO enhanced azithromycin in vivo in a K. pneumoniae septicemia model. PPMOs targeting the homologous resistance-nodulation-division (RND)-efflux system in P. aeruginosa, MexAB-OprM, also enhanced potency to several classes of antibiotics in a panel of strains and in a cell culture infection model. These data suggest that PPMOs can be used as an adjuvant in antibiotic therapy to increase the efficacy or extend the spectrum of useful antibiotics against a variety of Gram-negative infections.

AB - Overexpression of bacterial efflux pumps is a driver of increasing antibiotic resistance in Gram-negative pathogens. The AcrAB-TolC efflux pump has been implicated in resistance to a number of important antibiotic classes including fluoroquinolones, macrolides, and β-lactams. Antisense technology, such as peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs), can be utilized to inhibit expression of efflux pumps and restore susceptibility to antibiotics. Targeting of the AcrAB-TolC components with PPMOs revealed a sequence for acrA, which was the most effective at reducing antibiotic efflux. This acrA-PPMO enhances the antimicrobial effects of the levofloxacin and azithromycin in a panel of clinical Enterobacteriaceae strains. Additionally, acrA-PPMO enhanced azithromycin in vivo in a K. pneumoniae septicemia model. PPMOs targeting the homologous resistance-nodulation-division (RND)-efflux system in P. aeruginosa, MexAB-OprM, also enhanced potency to several classes of antibiotics in a panel of strains and in a cell culture infection model. These data suggest that PPMOs can be used as an adjuvant in antibiotic therapy to increase the efficacy or extend the spectrum of useful antibiotics against a variety of Gram-negative infections.

KW - antisense

KW - bacterial efflux pumps

KW - Escherichia coli

KW - Klebsiella pneumoniae

KW - peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs)

KW - Pseudomonas aeruginosa

UR - http://www.scopus.com/inward/record.url?scp=85067979410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067979410&partnerID=8YFLogxK

U2 - 10.1021/acsinfecdis.9b00123

DO - 10.1021/acsinfecdis.9b00123

M3 - Article

JO - ACS Infectious Diseases

JF - ACS Infectious Diseases

SN - 2373-8227

ER -